JULY 2020

HelixBind awarded $3M Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease.

​

JUNE 2020

HelixBind awarded $3M Grant from NIH and expands Clinical Advisory Board to accelerate development of its diagnostic platform for invasive infections.

​

December 2019

HelixBind awarded $4M of additional funding by CARB-X to continue development of RaPID diagnostic platform.

​

MARCH 2018

HelixBind awarded up to $2M from CARB- X to combat the rise of antimicrobial resistant pathogens.

​

SEPTEMBER 2017

​

HelixBind closes $3M in Series-A financing

AUGUST 2017

​

HelixBind awarded a $2M Phase II SBIR from the National Institutes of Health (NIH) to further development of a culture-free, sample-to-answer test for detecting and identifying microbial pathogens prevalent in neonatal sepsis.

APRIL 2017

​

USPTO issues HelixBind patent US 14/402,028 covering methods and compositions of matter for diagnosing sepsis

​

AUGUST 2016

​

HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens

​

MARCH 2016

​

HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours.

JULY 2015

​

HelixBind awarded $1.5M Phase II SBIR from the National Institutes of Health (NIH)

​

MARCH 2014

​

HelixBind closes $1.65M seed financing

​